Home › Funds › PSP Research LLC › STOK
PSP Research LLC position in STOK
STOKE THERAPEUTICS INC · Health Care
PSP Research LLC reported holding 9,000 shares of STOK (STOKE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$234K, representing 0.16% of its reported portfolio and ranking #27 among its reported holdings. PSP Research LLC has disclosed STOK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR
How PSP Research LLC's STOK position evolved
PSP Research LLC first disclosed a stake in STOK in Q4 2025 at 16,621 shares (US$528K). Across 4 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 9,000 shares valued at US$234K — a reduction of -3,000 shares quarter over quarter.. Notable position changes include a 28% trim in Q1 2026 (shares were roughly flat over the following quarter), a 25% trim in Q3 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 16.62K | $527.55K | New |
| Q1 2026 | 12.00K | $390.72K | Reduce |
| Q2 2026 | 12.00K | $392.64K | Hold |
| Q3 2026 | 9.00K | $234.00K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STOK and 13F data
STOK (STOKE THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in STOK — the largest reported positions include RTW INVESTMENTS, LP (US$184.0M), Lynx1 Capital Management LP (US$132.1M), Redmile Group, LLC (US$129.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STOK
- RTW INVESTMENTS, LP 5.62M sh · $184.00M · Q2 2026
- Lynx1 Capital Management LP 4.04M sh · $132.14M · Q2 2026
- Redmile Group, LLC 3.95M sh · $129.11M · Q2 2026
- BAKER BROS. ADVISORS LP 3.34M sh · $109.18M · Q2 2026
- TORONTO DOMINION BANK 3.17M sh · $103.83M · Q2 2026
- BVF INC/IL 2.55M sh · $83.36M · Q2 2026
- Siren, L.L.C. 2.00M sh · $65.29M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.82M sh · $59.66M · Q2 2026
- EcoR1 Capital, LLC 735.00K sh · $24.05M · Q2 2026
- MPM BioImpact LLC 723.31K sh · $23.67M · Q2 2026
- Opaleye Management Inc. 700.00K sh · $22.90M · Q2 2026
- Troluce Capital Advisors LLC 496.42K sh · $16.24M · Q2 2026
More on PSP Research LLC
FAQ
How long has PSP Research LLC held STOK?
PSP Research LLC has disclosed STOK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is PSP Research LLC's current position in STOK?
As of Q3 2026, PSP Research LLC holds 9.00K shares of STOK (STOKE THERAPEUTICS INC), valued at $234.00K, representing 0.16% of its reported portfolio and ranking #27.
Has PSP Research LLC been buying or selling STOK?
In the latest 13F filing (Q3 2026), PSP Research LLC reduced its position in STOK.
Which other funds hold STOK?
Other major institutional holders of STOK include RTW INVESTMENTS, LP, Lynx1 Capital Management LP, Redmile Group, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.